Publication: Block of purinergic P2X7R inhibits tumor growth in a c6 glioma brain tumor animal model
Issued Date
2011-01-01
Resource Type
ISSN
00223069
Other identifier(s)
2-s2.0-78650677507
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Neuropathology and Experimental Neurology. Vol.70, No.1 (2011), 13-22
Suggested Citation
Jae K. Ryu, Nattinee Jantaratnotai, Maria C. Serrano-Perez, Patrick L. McGeer, James G. McLarnon Block of purinergic P2X7R inhibits tumor growth in a c6 glioma brain tumor animal model. Journal of Neuropathology and Experimental Neurology. Vol.70, No.1 (2011), 13-22. doi:10.1097/NEN.0b013e318201d4d4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12761
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Block of purinergic P2X7R inhibits tumor growth in a c6 glioma brain tumor animal model
Other Contributor(s)
Abstract
We examined the expression and pharmacological modulation of the purinergic receptor P2X 7 R in a C6 glioma model. Intrastriatal injection of C6 cells induced a time-dependent growth of tumor; at 2weeks postinjection immunohistochemical analysis demonstrated higher levels of P2X 7 R in glioma-injected versus control vehicle-injected brains. P2X 7 R immunoreactivity colocalized with tumor cells and microglia, but not endogenous astrocytes. Intravenous administration of the P2X 7 R antagonist brilliant blue G (BBG) inhibited tumor growth in a spatially dependent manner from the C6 injection site. Treatment with BBG reduced tumor volume by 52% versus that in controls. Double immunostaining indicated that BBG treatment did not alter microgliosis, astrogliosis, or vasculature vessels in C6-injected animals. In vitro, BBG reduced the expression of P2X 7 R and glioma chemotaxis induced by the P2X 7 R ligand, 2′,3′-O-(4- benzoyl-benzoyl)adenosine triphosphate (BzATP). Immunohistochemical staining of human glioblastoma tissue samples demonstrated greater expression of P2X 7 R compared to control nontumor samples. These results suggest that the efficacy of BBG in inhibiting tumor growth is primarily mediated by direct actions of the compound on P2X 7 R in glioma cells and that pharmacological inhibition of this purinergic receptor might serve as a strategy to slow the progression of brain tumors. © 2010 by the American Association of Neuropathologists, Inc.